Skip to main
MMSI

MMSI Stock Forecast & Price Target

MMSI Analyst Ratings

Based on 9 analyst ratings
Buy
Strong Buy 33%
Buy 56%
Hold 11%
Sell 0%
Strong Sell 0%

Bulls say

Merit Medical Systems Inc. has experienced significant growth in its financial performance, with gross margins expanding from 48.8% in FY22 to an estimated 53.4% in 2025, reflecting a strong upward trajectory of 460 basis points. The company's overall revenue saw an increase of approximately 11%, driven primarily by the Cardiovascular segment, which similarly grew around 11% as reported. Additionally, a notable rise in physician reimbursement rates, which increased by approximately 27% for certain procedures, is expected to further enhance device adoption and accelerate organic growth in vascular-based interventions.

Bears say

Merit Medical Systems Inc. has reported disappointing OEM revenue of $48.1 million, falling short of expectations and indicating potential issues with product demand. Concerns are amplified by risks related to margin performance, free cash flow, and slower growth in key markets like China, which could hinder the company’s overall financial health. Additionally, the bear case scenario suggests that the firm may experience revenue growth of 5% or lower, driven by challenges from recent acquisitions, unsuccessful product launches, and external economic pressures, all of which could negatively impact operating margins and earnings.

MMSI has been analyzed by 9 analysts, with a consensus rating of Buy. 33% of analysts recommend a Strong Buy, 56% recommend Buy, 11% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Merit Medical Systems and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Merit Medical Systems (MMSI) Forecast

Analysts have given MMSI a Buy based on their latest research and market trends.

According to 9 analysts, MMSI has a Buy consensus rating as of Mar 25, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $103.56, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $103.56, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Merit Medical Systems (MMSI)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.